Rivaroxaban
Indication
Prevention of stroke and systemic embolism in people with atrial fibrillation (NICE TA256)
NICE TA256 - Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
Green
Brand:
Xarelto®
Nice TA:
256
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Cardiovascular system
Background
Where a DOAC is considered to be the most appropriate anticoagulant, edoxaban is to be used 1st line for patients with non-valvular AF unless there is a specific clinical reason not to do so.
Recommendation
LSCMMG Recommendation:
Green
Reason for decision:
Suitable for initiation in primary care
Supporting documents: